First US Trial Over Zantac's Alleged Cancer-Causing Properties Set For November In California
Portfolio Pulse from Vandana Singh
The first U.S. trial over the alleged cancer-causing properties of the antacid medication Zantac is set to begin on November 13 in California. The lawsuit alleges that Zantac is responsible for causing nine different forms of cancer. Several lawsuits have been filed against GSK, Sanofi SA, Pfizer Inc, and Boehringer Ingelheim, who all sold Zantac at various times. The outcome of the trial could influence broader settlement negotiations.
July 03, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
GSK, one of the sellers of Zantac, is involved in the upcoming trial. The outcome could potentially lead to financial liabilities.
The upcoming trial could potentially lead to financial liabilities for GSK if the court rules against them. This could negatively impact their stock price in the short term.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 75
NEGATIVE IMPACT
Pfizer Inc, one of the sellers of Zantac, is involved in the upcoming trial. The outcome could potentially lead to financial liabilities.
The upcoming trial could potentially lead to financial liabilities for Pfizer Inc if the court rules against them. This could negatively impact their stock price in the short term.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 75
NEGATIVE IMPACT
Sanofi SA, one of the sellers of Zantac, is involved in the upcoming trial. The outcome could potentially lead to financial liabilities.
The upcoming trial could potentially lead to financial liabilities for Sanofi SA if the court rules against them. This could negatively impact their stock price in the short term.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 75